SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 10-QSB

(Mark One)
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2004

OR

[ ] TRANSITION REPORT UNDER SECTION 13 OF 15(D) OF THE EXCHANGE ACT OF 1934

From the transition period from ___________ to ____________.

Commission File Number 01-28911

NATIONAL HEALTHCARE TECHNOLOGY, INC.
(Exact name of small business issuer as specified in its charter)

| Colorado | 91-1869677 |
|---|---|
| (State or other jurisdiction of incorporation or organization) | (IRS Employer Identification No.) |

20700 Ventura Boulevard, #227, Woodland Hills, California 91364
(Address of principal executive offices)

(818) 227-9494
(Issuer's telephone number)

N/A
(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days:

Yes[X] No [_]

As of August 8, 2003 7,855,500 shares of Common Stock of the issuer were outstanding.

PART I. FINANCIAL INFORMATION

NATIONAL HEALTHCARE TECHNOLOGY, INC.
(A DEVELOPMENT STAGE COMPANY)
BALANCE SHEET
JUNE 30, 2004
(UNAUDITED)

| | |
|---|---|
| Assets | $ -- |
| LIABILITIES AND STOCKHOLDERS' DEFICIT | |
| Current liabilities | |
| Accounts payable: | |
| Trade | $ 70,908 |
| Crown Partners', Inc. | 93,309 |
| Total current liabilities | 164,217 |
| STOCKHOLDERS' DEFICIT: | |
| Preferred stock, $.01 par value, 500,000,000 shares authorized, no shares issued and outstanding | -- |
| Common stock, $.001 par value, 25,000,000 shares authorized, 7,855,500 shares issued and outstanding | 7,855 |
| Additional paid in capital | 1,237,439 |
| Accumulated deficit | (1,409,511) |
| Total Stockholders' Deficit | (164,217) |
| TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT | $ -- |

NATIONAL HEALTHCARE TECHNOLOGY, INC.
(A DEVELOPMENT STAGE COMPANY)
STATEMENTS OF OPERATIONS
THREE AND SIX MONTHS ENDED JUNE 30, 2004 AND 2003 AND
FEBRUARY 29, 1996 (INCEPTION) THROUGH JUNE 30, 2004
(UNAUDITED)

| | THREE MONTHS ENDED JUNE 30, | | NINE MONTHS ENDED JUNE 30, | | |
|---|---|---|---|---|---|
| | 2004 | 2003 | 2004 | 2003 | |
| Revenue | $ -- | $ -- | $ -- | $ -- | $ |
| Expenses: | | | | | |

| | | | | |
|---|---|---|---|---|
| Development costs | -- | -- | -- | -- |
| General and administrative | 14,346 | 11,426 | 28,578 | 27,673 |
| | 14,346 | 11,426 | 28,578 | 27,673 |
| Net loss before income taxes | (14,346) | (11,426) | (28,578) | (27,673) |
| Income taxes | -- | -- | -- | -- |
| Net loss | $ (14,346) | $ (11,426) | $ (28,578) | $ (27,673) |
| Basic net loss per common share | $ (0.00) | $ (0.00) | $ (0.00) | $ (0.00) |
| Weighted average shares outstanding | 7,855,500 | 7,855,500 | 7,855,500 | 7,855,500 |

NATIONAL HEALTHCARE TECHNOLOGY, INC.
(A DEVELOPMENT STAGE COMPANY)
STATEMENTS OF CASH FLOWS
THREE AND SIX MONTHS ENDED JUNE 30, 2004 AND 2003 AND
FEBRUARY 29, 1996 (INCEPTION) THROUGH JUNE 30, 2004
(UNAUDITED)

| | NINE MONTHS ENDED JUNE 30, 2004 | NINE MONTHS ENDED JUNE 30, 2003 | INCEPTION THROUGH JUNE 30, 2004 |
|---|---|---|---|
| Cash flows from operating activities: | | | |
| Net loss | $ (28,578) | (27,673) | $ (1,409,511) |
| Adjustments to reconcile net loss to net cash provided by (used in) operating activities: | | | |
| Depreciation and amortization | -- | -- | 22,977 |
| Common stock issued for settlement of interest Expense | -- | -- | 12,900 |
| Common stock issued for services | -- | -- | 217,900 |
| Loss on abandoned assets | -- | -- | 120,387 |
| Gain on sale of assets | -- | -- | (500) |
| Income from sale of abandoned assets | -- | -- | (9,578) |
| Changes in operating assets and liabilities | | | |
| Accounts payable | 28,578 | 27,673 | 165,020 |
| Net cash used in operating activities | -- | -- | (880,405) |
| Cash flows from investing activities: | | | |
| Purchase of property and equipment | -- | -- | (87,314) |

| | | | |
|---|---|---|---|
| Proceeds from the sale of equipment | -- | -- | 15,078 |
| Net cash used in investing activities | -- | -- | (72,236) |
| Cash flows from financing activities: | | | |
| Proceeds from notes payable | -- | -- | 217,200 |
| Payments on notes payable | -- | -- | (20,000) |
| Proceeds from the sale of common stock, net | -- | -- | 755,441 |
| Net cash provided by financing activities | -- | -- | 952,641 |
| Net increase (decrease) in cash and cash equivalents | -- | -- | -- |
| Cash at beginning of period | -- | -- | -- |
| Cash at end of period | $ -- | $ -- | $ -- |

NATIONAL HEALTHCARE TECHNOLOGY, INC.
(A DEVELOPMENT STAGE COMPANY)
NOTES TO FINANCIAL STATEMENTS
(UNAUDITED)

Note 1 - BASIS OF PRESENTATION

The balance sheet of the Company as of June 30, 2004, the related statements of operations for the three months and nine months ended June 30, 2004 and 2003 and the statements of cash flows for the nine months ended June 30, 2004 and 2003 included in the financial statements have been prepared by the Company without audit. In the opinion of management, the accompanying financial statements include all adjustments (consisting of normal, recurring adjustments) necessary to summarize fairly the Company's financial position and results of operations. The results of operations for the three months ended June 30, 2004 are not necessarily indicative of the results of operations for the full year or any other interim period. The information included in this Form 10-QSB should be read in conjunction with Management's Discussion and Analysis and Financial Statements and notes thereto included in the Company's September 30, 2003 Form 10-KSB.

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS

THIS REPORT CONTAINS FORWARD LOOKING STATEMENTS WITHIN THE MEANING OF SECTION 27A OF THE SECURITIES ACT OF 1933, AS AMENDED AND SECTION 21E OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. THE COMPANY'S ACTUAL RESULTS COULD DIFFER MATERIALLY FROM THOSE SET FORTH ON THE FORWARD LOOKING STATEMENTS AS A RESULT OF THE RISKS SET FORTH IN THE COMPANY'S FILINGS WITH THE SECURITIES AND EXCHANGE COMMISSION, GENERAL ECONOMIC CONDITIONS, AND CHANGES IN THE ASSUMPTIONS USED IN MAKING SUCH FORWARD LOOKING STATEMENTS.

GENERAL

National Healthcare Technology, Inc. (the "Company") was organized February 29, 1996 as "Patriot Holding Corporation" and subsequently changed its name to "National Healthcare Technology, Inc." on August 26, 1996. Between 1996 and 1999, the Company was unsuccessful in raising sufficient capital to begin and complete a proposed double-blind study of an intravenous drug called Magkelate. The Company did raise $1,000,000 which was used to pay its operating expenses and general and administrative expenses as well as expenses related to starting the double-blind study. Following its inability to raise capital and needing to conserve its financial resources, the Company dismissed all of its employees in early 1999. The developer of Magkelate passed away in the fall of 1999 and the Magkelate patent has expired. Since 1999, the Company has been substantially inactive. The Company is in the development stage as defined in Statement of Financial Accounting Standards No. 7.

When used in this Form 10-QSB, the words "anticipate", "estimate", "expect", "project" and similar expressions are intended to identify forward-looking statements. Such statements are subject to certain risks, uncertainties and assumptions including the possibility that the Company's proposed plan of operation will fail to generate projected revenues. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, estimated or projected.

LIQUIDITY AND CAPITAL RESOURCES

The Company is in the development stage and since inception has experienced no significant change in liquidity or capital resources or stockholders equity other than the receipt of $1,000,000 from an offering conducted under Rule 504 of Regulation D in 1997. The Company's balance sheet as of June 30, 2004 reflects no assets and limited liabilities. Further, there exists no agreements or understandings with regard to loan agreements by or with the Officers, Directors, principals, affiliates or shareholders of the Company.

The Company is continuing to search for suitable merger candidates or other businesses to become involved in so that it can commence operations and generate revenues to continue paying its bills.

The Company will attempt to carry out its plan of business and hopes to enter into a business combination with another entity. The Company cannot predict to what extent its lack of liquidity and capital resources will hinder its business plan prior to the consummation of a business combination.

RESULTS OF OPERATIONS

During the period from November 5, 1989 (inception) through September 30, 2003, the Company engaged in limited operations and attempted to initiate its double blind study of its drug, Magkelate. The Company received no revenues during this period. The capital raised was expended for general office and administrative expenses and the proposed double-blind study of Magkelate, which double-blind study the Company was unable to start due to lack of capital.

For the nine months ended June 30, 2004, the Company had no revenue and its expenses were $28,578 resulting in a net loss for the nine months of $28,578 compared to no revenue and expenses of $27,673 for the nine months ended June 30, 2003 and a net loss of $27,673 for the nine months then ended.

For the three months ended June 30, 2004, the Company had no revenue and its expenses were $14,346 resulting in a net loss for the quarter of $14,346 compared to no revenue and expenses of $11,426 for the three months ended June 30, 2003 and a net loss of $11,426.

The Company anticipates that until a business combination is completed with an acquisition candidate, it will not generate revenue and may operate at a loss after completing a business combination, depending upon the performance of the acquired business. The Company will attempt to carry out its business plan as discussed above. The Company cannot predict to what extent its lack of liquidity and capital resources will hinder its business plan prior to the consummation of a business combination.

NEED FOR ADDITIONAL FINANCING

The Company's has no working capital to meet the Company's cash needs, including the costs of compliance with the continuing reporting requirements of the Securities Exchange Act of 1934, as amended. Once a business combination is completed, the Company's need for additional financing is likely to increase substantially.
No commitments to provide additional funds have been made by management or other stockholders. Accordingly, there can be no assurance that any funds will be available to the Company to allow it to cover its expenses.

The Company might seek to compensate providers of services by issuances of stock in lieu of cash.

DESCRIPTION OF PROPERTIES

The Company presently has no office space.

EMPLOYEES

As of June 30, 2004, the Company had no employees.

New Accounting Pronouncements

In April 2002, the FASB approved for issuance Statements of Financial Accounting Standards No. 145, "Rescission of FASB Statements No. 4, 44 and 64, Amendment of SFAS 13, and Technical Corrections" ("SFAS 145"). SFAS 145 rescinds previous accounting guidance, which required all gains and losses from extinguishment of debt be classified as an extraordinary item. Under SFAS 145 classification of debt extinguishment depends on the facts and circumstances of the transaction. SFAS 145 is effective for fiscal years beginning after May 15, 2002 and is not expected to have a material effect on the Company's financial position or results of its operations.

In July 2002, the FASB issued Statements of Financial Accounting Standards No. 146, "Accounting for Costs Associated with Exit or Disposal Activities" (SFAS 146). SFAS 146 requires companies to recognize costs associated with exit or disposal activities when they are incurred rather than at the date of a commitment to an exit or disposal plan. Examples of costs covered by SFAS 146 include lease termination costs and certain employee severance costs that are associated with a restructuring, discontinued operation, plant closing, or other exit or disposal activity. SFAS 146 is to be applied prospectively to exit or disposal activities initiated after December 31, 2002. The adoption of SFAS 146 is not expected to have a material effect on the Company's financial position or results of its operations.

In December 2002, the FASB issued Statements of Financial Accounting Standards No. 148 "Accounting for Stock-Based Compensation--Transition and Disclosure--an amendment of FASB Statement No. 123, This Statement amends FASB Statement No. 123, Accounting for Stock-Based Compensation, to provide alternative methods of transition for a voluntary change to the fair value based method of accounting for stock-based employee compensation. In addition, this Statement amends the disclosure requirements of Statement 123 to require prominent disclosures in both annual and interim financial statements about the method of accounting for stock-based employee compensation and the effect of the method used on reported results. The adoption of SFAS 148 is not expected to have a material effect on the Company's financial position or results of its operations.

Inflation

The Company's results of operations have not been affected by inflation and management does not expect inflation to have a significant effect on its operations in the future.

ITEM 3. CONTROLS AND PROCEDURES

Based on the evaluation of the Company's disclosure controls and procedures by Mr. Charles Smith, both the chief executive officer and chief accounting officer of the company, as of a date within 90 days of the filing date of this quarterly report, such officer has concluded that the Company's disclosure controls and procedures are effective in ensuring that information required to be disclosed by the Company in the reports that it files or submits under the Securities and Exchange Act of 1934, as amended, is recorded, processed, summarized and reported, within the time period specified by the Securities and Exchange Commission's rules and forms.

There were no significant changes in the Company's internal controls or in other factors that could significantly affect these controls subsequent to the date of their evaluation, including any corrective actions with regard to significant deficiencies and material weaknesses.

PART II - OTHER INFORMATION

Items No. 1, 2, 3, 4, 5 - Not applicable.

Item 6. EXHIBITS AND REPORTS ON FORM 8-K

a) Exhibits - None.

b) Reports on Form 8-K

There were no reports on Form 8-K filed during the quarter for which this report is filed.

SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

NATIONAL HEALTHCARE TECHNOLOGY, INC.

Date: August 19, 2004

By: /s/ Charles Smith

-------------------------------------

Charles Smith

CEO, CFO